EXAS241018P85000
- 39.64
- 0.000.00%
Exact Sciences Newsroom
Leerink Partners Maintains Exact Sciences(EXAS.US) With Buy Rating
Buy Rating for Exact Sciences as Cologuard Plus Poised for Growth and Upside Pricing Potential
TD Cowen Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $80
Analysts Are Bullish on These Healthcare Stocks: Exact Sciences (EXAS), AdaptHealth (AHCO)
Wolfe Research Maintains Exact Sciences(EXAS.US) With Buy Rating, Cuts Target Price to $75
Exact Sciences Analyst Ratings
BTIG Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $82
BTIG Sticks to Their Buy Rating for Exact Sciences (EXAS)
Jefferies Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $84
A Quick Look at Today's Ratings for Exact Sciences(EXAS.US), With a Forecast Between $75 to $84
Buy Rating Affirmed for Exact Sciences on Robust CRC Test Results and Strategic Pipeline Advancements
Exact Sciences Price Target Maintained With a $75.00/Share by Canaccord Genuity
CCORF Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $75
Analysts Offer Insights on Healthcare Companies: Seres Therapeutics (MCRB), BioMarin Pharmaceutical (BMRN) and Exact Sciences (EXAS)
Piper Sandler Maintains Exact Sciences(EXAS.US) With Buy Rating, Raises Target Price to $85
Exact Sciences Is Maintained at Overweight by Piper Sandler
Exact Sciences Analyst Ratings
Evercore Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $72
Buy Rating for Exact Sciences: Anticipated Growth From Upcoming Catalysts and Competitive Pricing
Buy Rating Affirmed for Exact Sciences Amid Promising Cancer Screening Innovations and Strategic Advantages